Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses the rationale for the pivotal CheckMate-214 trial in advanced renal cell carcinoma.
Asim Amin, MD, PhD
Advertisement
Articles by Asim Amin, MD, PhD
Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses methods of evaluating response to immunotherapy in renal cell carcinoma (RCC).
Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses how to manage toxicities associated with immunotherapy and tyrosine kinase inhibitor combinations in renal cell carcinoma.
Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses next steps with immunotherapy in the treatment of patients with advanced renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr. Amin on Next Steps With Immunotherapy in Advanced RCCPublished: October 24th 2018 | Updated:
Dr. Amin on Toxicities With Immunotherapy/TKI Combinations in RCCPublished: October 30th 2018 | Updated:
Dr. Amin on Evaluating Response to Immunotherapy in RCCPublished: November 3rd 2018 | Updated:
Dr. Amin on CheckMate-214 Trial in RCCPublished: December 6th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5